keyword
MENU ▼
Read by QxMD icon Read
search

oxybutynin

keyword
https://www.readbyqxmd.com/read/28093646/mechanisms-of-inhibitory-action-of-trk-130-naltalimide-a-%C3%AE-opioid-receptor-partial-agonist-on-the-micturition-reflex
#1
Morihiro Fujimura, Naoki Izumimoto, Sayoko Kanie, Ryosuke Kobayashi, Satoru Yoshikawa, Shinobu Momen, Mikito Hirakata, Toshikazu Komagata, Satoshi Okanishi, Masashi Iwata, Tadatoshi Hashimoto, Takayuki Doi, Naoki Yoshimura, Koji Kawai
PURPOSE: To clarify the mechanism of inhibitory action of TRK-130 (Naltalimide), a unique µ-opioid receptor partial agonist, on the micturition reflex. METHODS: The effect of TRK-130 on isovolumetric rhythmic bladder contractions (RBCs) was examined in guinea pigs, the effect of which was clarified by co-treatment with naloxone or in spinal cord transection. The effect of TRK-130 on urodynamic parameters was also observed in guinea pigs. In addition, the effect of TRK-130 on bladder contraction induced by peripheral stimulation of the pelvic nerve was investigated in rats...
January 16, 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28091711/anticholinergic-prescription-are-healthcare-professionals-the-real-burden
#2
George Araklitis, Ganesh Thiagamoorthy, Jo Hunter, Angie Rantell, Dudley Robinson, Linda Cardozo
INTRODUCTION AND HYPOTHESIS: Anticholinergic medication is the medical treatment for overactive bladder (OAB). These drugs can act on the central nervous system and can lead to cognitive decline, dementia, and potentially death. Patients taking drugs with anticholinergic effects increase their anticholinergic burden-defined as the cumulative effect of taking one or more drugs that can have adverse effects. When prescribing anticholinergic medication for the elderly, we must choose the right drug...
January 13, 2017: International Urogynecology Journal
https://www.readbyqxmd.com/read/28025920/impact-of-overactive-bladder-step-therapy-policies-on-medication-utilization-and-expenditures-among-treated-medicare-members
#3
Ibrahim M Abbass, Eleanor O Caplan, Daniel B Ng, Rita Kristy, Carol R Schermer, Pamela Bradt, Jenna M Collins, Wai Man Maria Chan, Brandon T Suehs
BACKGROUND: The impact of formulary management strategies on utilization and expenditures in overactive bladder (OAB) treatment has not been extensively investigated. In 2013, step therapy (ST) policies for 2 branded OAB treatments, mirabegron and fesoterodine, were removed from Humana Medicare Advantage Prescription Drug (MAPD) plans and Medicare prescription drug plans (PDP), allowing for an examination of the effect of ST policies on OAB medication use patterns and costs. OBJECTIVE: To assess the impact of removal of formulary restriction policies for mirabegron and fesoterodine on medication utilization patterns and costs associated with OAB treatment in Medicare patients...
January 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28001258/translation-and-validation-of-hyperhidrosis-disease-severity-scale
#4
Andrea Yasbek Monteiro Varella, Juliana Maria Fukuda, Marcelo Passos Teivelis, José Ribas Milanez DE Campos, Paulo Kauffman, Gabriel Grizzo Cucato, Pedro Puech-Leão, Nelson Wolosker
Introduction: The evaluation of patients with hyperhidrosis (HH) can be accomplished, among other ways, through questionnaires and scales. The Hyperhidrosis Disease Severity Scale (HDSS) has been used as a simple and quick tool to perform this evaluation. Although HDSS has been well established in several languages, it has not been translated into Portuguese, restricting its specific use for Brazilian patients. The aim of this study was to translate HDSS into Portuguese and validate it in a sample of Brazilian subjects...
December 2016: Revista da Associação Médica Brasileira
https://www.readbyqxmd.com/read/27976476/treatment-of-primary-hyperhidrosis-with-oral-anticholinergic-medications-a-systematic-review
#5
REVIEW
Lucinda Cruddas, Daryll M Baker
BACKGROUND: Primary hyperhidrosis is a condition characterised by excessive sweating. Patients are treated off-license with oral anticholinergic medications, and report adverse events associated with systemic anticholinergic interactions. OBJECTIVES: This review assesses clinical evidence of efficacy, impact on quality of life and adverse events associated with oral anticholinergic therapy for primary hyperhidrosis. METHODS: PRISMA guidelines were implemented to complete a systematic review (PROSPERO:CRD42016036326)...
December 15, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27935011/electrical-stimulation-with-non-implanted-electrodes-for-overactive-bladder-in-adults
#6
REVIEW
Fiona Stewart, Luis F Gameiro, Regina El Dib, Monica O Gameiro, Anil Kapoor, Joao L Amaro
BACKGROUND: Several options exist for managing overactive bladder (OAB), including electrical stimulation (ES) with non-implanted devices, conservative treatment and drugs. Electrical stimulation with non-implanted devices aims to inhibit contractions of the detrusor muscle, potentially reducing urinary frequency and urgency. OBJECTIVES: To assess the effects of ES with non-implanted electrodes for OAB, with or without urgency urinary incontinence, compared with: placebo or any other active treatment; ES added to another intervention compared with the other intervention alone; different methods of ES compared with each other...
December 9, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27878051/anticholinergics-for-overactive-bladder-temporal-trends-in-prescription-and-treatment-persistence
#7
Christopher J D Wallis, Colin Lundeen, Nicole Golda, Hilary Brotherhood, Peter Pommerville, Lesley Carr
INTRODUCTION: We sought to understand the contemporary pharmacologic management of overactive bladder (OAB) in a single-payer system. We examined temporal trends in the use of anticholinergic medications and assessed whether the likelihood of patients changing their anticholinergic therapy was predicted by their current therapy. METHODS: We conducted a retrospective, population-based analysis of prescription records from the PharmaNet database in BC, Canada. We identified patients treated with one or more anticholinergic prescriptions between 2001 and 2009...
August 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/27872944/-multiple-eccrine-hidrocystomas-on-the-lower-forehead-and-nose-of-a%C3%A2-60-year-old-man
#8
J K Winkler, W Hartschuh, A Enk, F Toberer
Multiple eccrine hidrocystomas are benign cystic skin lesions which originate from the sweat gland ducts and typically affect women's midfacial area. Sweating may lead to an increase in size of the translucent papules. In some cases hidrocystomas are associated with other diseases such as Parkinson's disease. Treatment options include laser, topical and systemic anticholinergic drugs (glycopyrrolate, clonidine, atropine, and oxybutynin), whereby therapeutic success is limited in most cases.
November 21, 2016: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/27845692/-expert-opinion-about-the-use-of-transdermic-oxybutynin-in-spain-for-the-treatment-of-adult-overactive-bladder
#9
Carlos Müller-Arteaga, Salvador Arlandis Guzmán, María Fernanda Lorenzo Gómez, Carlos Errando-Smet, Raquel González López, Javier Cambronero Santos, José Luis Gutiérrez Baños, Manuel Sánchez Marcos, Antonio Ortiz Gamiz, Sergio Merino Salas, Roberto Martínez Rodriguez, Ivan Olano Grasa
OBJECTIVES: To define the different characteristics of transdermal oxybutynin (TO) for the treatment of overactive bladder in adults, to know the barriers for the use of this drug and to establish proposals to minimize these barriers. METHODS: Local sessions were held with 111 urologists from all over the country divided into 12 sessions. They were moderated by a brainstorming technique led by an external consultant. RESULTS: 75% of experts believe that tolerability and clinical efficacy (50%) are the most important attributes to choose this formulation, being the lack of scientific publications the least valued (12%)...
November 2016: Archivos Españoles de Urología
https://www.readbyqxmd.com/read/27760081/extended-release-oxybutynin-therapy-for-vasomotor-symptoms-in-women-a-randomized-clinical-trial
#10
James A Simon, Tatiana Gaines, Katherine D LaGuardia
OBJECTIVE: Assess effects of once-daily, extended-release oxybutynin chloride on frequency and severity of vasomotor symptoms in healthy, postmenopausal symptomatic women. METHODS: A 12-week, multicenter, double-blind, placebo-controlled, phase 2 clinical trial randomized naturally postmenopausal women experiencing at least seven moderate-to-severe vasomotor symptoms daily to oxybutynin 15 mg once daily (n = 73) or placebo (n = 75). Co-primary outcomes were the change from baseline to week 12 in the frequency and severity of moderate-to-severe vasomotor symptoms...
November 2016: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/27738922/a-short-review-of-drug-food-interactions-of-medicines-treating-overactive-bladder-syndrome
#11
Paweł Paśko, Tomasz Rodacki, Renata Domagała-Rodacka, Danuta Owczarek
Background Overactive bladder syndrome is a condition where one or more of the symptoms such as pollakiuria, urgent need to urinate, nocturia and urinary incontinence is observed. Its prevalence ranges between 7 and 27 % in men and 9-43 % in women. The role of a pharmacist is to educate the patient on medications administration scheme, and drug interactions with particular food or food components. Aim of the review To assess a potential impact of food and fruit juice on the pharmacokinetic and therapeutic effects of medications used in treating overactive bladder syndrome...
December 2016: International Journal of Clinical Pharmacy
https://www.readbyqxmd.com/read/27681701/antimuscarinic-medication-use-in-elderly-patients-with-overactive-bladder
#12
Nandita Kachru, Sneha Sura, Satabdi Chatterjee, Rajender R Aparasu
BACKGROUND: Antimuscarinic medications are the first-line pharmacological treatment for overactive bladder (OAB); however, little is known about the utilization pattern of antimuscarinic agents in elderly patients with OAB. OBJECTIVE: This study examined the prevalence and predictors of antimuscarinic medication prescribing in elderly patients with OAB, using national ambulatory survey data. METHODS: This cross-sectional study utilized the 2009-2010 National Ambulatory Medical Care Survey and the outpatient component of the National Hospital Ambulatory Medical Care Survey...
October 2016: Drugs & Aging
https://www.readbyqxmd.com/read/27680597/role-of-gabapentin-and-anticholinergics-in-management-of-neurogenic-bladder-after-repair-of-spina-bifida-a-randomized-controlled-study
#13
Vedarth Dash, Monika Bawa, J K Mahajan, Ravi P Kanojia, Ram Samujh, K L N Rao
BACKGROUND: Anticholinergics are well established in the management of neurogenic bladders. However, some patients do have sub-optimal response or severe side effects. This study is designed to assess and compare efficacy of gabapentin with oxybutynin in neurogenic bladders after surgery for spina bifida. METHODS: Patients were randomized into three groups after urodynamic studies and started on oxybutynin, gabapentin, and combination of both, respectively. Thorough clinical and urodynamic reassessment was done at 6months and one year after starting treatment...
December 2016: Journal of Pediatric Surgery
https://www.readbyqxmd.com/read/27631556/development-of-a-novel-simplified-pbpk-absorption-model-to-explain-the-higher-relative-bioavailability-of-the-oros%C3%A2-formulation-of-oxybutynin
#14
Andrés Olivares-Morales, Avijit Ghosh, Leon Aarons, Amin Rostami-Hodjegan
A new minimal Segmented Transit and Absorption model (mSAT) model has been recently proposed and combined with intrinsic intestinal effective permeability (P eff,int ) to predict the regional gastrointestinal (GI) absorption (f abs ) of several drugs. Herein, this model was extended and applied for the prediction of oral bioavailability and pharmacokinetics of oxybutynin and its enantiomers to provide a mechanistic explanation of the higher relative bioavailability observed for oxybutynin's modified-release OROS® formulation compared to its immediate-release (IR) counterpart...
2016: AAPS Journal
https://www.readbyqxmd.com/read/27631249/strategies-for-the-prevention-of-catheter-related-bladder-discomfort-a-prisma-compliant-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#15
Baoji Hu, Chengbao Li, Mengzhi Pan, Ming Zhong, Yu Cao, Nannan Zhang, Hongbin Yuan, Hongwei Duan
BACKGROUND: The ideal measures to prevent postoperative catheter-related bladder discomfort (CRBD) remain unestablished. We conducted the systematic review and meta-analysis to clarify the significance of potential interventions. METHODS: We followed the Preferred Reporting Items for Systematic review and Meta-Analysis statement guidelines, and searched databases from MEDLINE, EMBASE, and referred Cochrane Library for randomized clinical trials (RCTs) published before December 2014...
September 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27619779/optimum-dose-of-once-daily-oxybutynin-patch-in-japanese-patients-with-overactive-bladder-a-randomized-double-blind-trial-versus-placebo
#16
Osamu Yamaguchi, Eiji Uchida, Naruhito Higo, Hidenao Minami, Shigeo Kobayashi, Hiroyuki Sato
OBJECTIVE: To evaluate the efficacy, safety, and optimum dose of once-daily oxybutynin patch for overactive bladder. METHODS: A randomized double-blind trial was conducted in patients with overactive bladder symptoms for ≥24 weeks, who received an oxybutynin patch (73.5 or 105 mg) or placebo once daily for 8 weeks. The primary endpoint was the change in the daily frequency of micturition from baseline to the end of study. RESULTS: A total of 579 patients were randomized to the placebo group (n = 164), 73...
September 2016: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/27614759/intravesical-treatment-for-interstitial-cystitis-painful-bladder-syndrome-a-network-meta-analysis
#17
Wei Zhang, Xiaojing Deng, Chunyu Liu, Xu Wang
INTRODUCTION AND HYPOTHESIS: Interstitial cystitis/painful bladder syndrome (IC/PBS) is a chronic inflammatory condition of the submucosal and muscular layers of the bladder. So far, there is no effective and targeted treatment strategy for IC/PBS. This study aimed to assess the efficacy and safety of intravesical instillation treatment in IC/PBS patients. METHODS: We searched various databases up to October 2015. A network meta-analysis was performed to compare global response assessment (GRA) for different treatment strategies, including botulinum toxin A (BoNTA), bacillus Calmette-Guerin (BCG), resiniferatoxin (RTX), lidocaine, chondroitin sulfate (CS), oxybutynin, and pentosan polysulfate (PPS)...
September 10, 2016: International Urogynecology Journal
https://www.readbyqxmd.com/read/27579830/estimated-budget-impact-of-increased-use-of-mirabegron-a-novel-treatment-for-overactive-bladder
#18
Sinem Perk, Ronald C Wielage, Noll L Campbell, Timothy M Klein, Anthony Perkins, Linda M Posta, Thomas Yuran, Robert W Klein, Daniel B Ng
BACKGROUND: Oral pharmacological treatment for overactive bladder (OAB) consists of antimuscarinics and the beta-3 adrenergic agonist mirabegron. Antimuscarinic adverse events (AEs) such as dry mouth, constipation, and blurry vision can result in frequent treatment discontinuation rates, leaving part of the OAB population untreated. Antimuscarinics also contribute to a patient's anticholinergic cognitive burden (ACB), so the Beers Criteria recommends cautious use of antimuscarinics in elderly patients who take multiple anticholinergic medications or have cognitive impairment...
September 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27574750/estimated-budget-impact-of-increased-use-of-mirabegron-a-novel-treatment-for-overactive-bladder
#19
Sinem Perk, Ronald C Wielage, Noll L Campbell, Timothy M Klein, Anthony Perkins, Linda M Posta, Thomas Yuran, Robert W Klein, Daniel B Ng
BACKGROUND: Oral pharmacological treatment for overactive bladder (OAB) consists of antimuscarinics and the beta-3 adrenergic agonist mirabegron. Antimuscarinic adverse events (AEs) such as dry mouth, constipation, and blurry vision can result in frequent treatment discontinuation rates, leaving part of the OAB population untreated. Antimuscarinics also contribute to a patient's anticholinergic cognitive burden (ACB), so the Beers Criteria recommends cautious use of antimuscarinics in elderly patients who take multiple anticholinergic medications or have cognitive impairment...
September 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27497508/preliminary-experience-with-transdermal-oxybutynin-patches-for-hyperhidrosis
#20
M Bergón-Sendín, A Pulido-Pérez, L C Sáez-Martín, R Suárez-Fernández
BACKGROUND AND OBJECTIVE: Hyperhidrosis is very common and has a considerable impact on patients' quality of life. While oral oxybutynin is associated with good response rates, adverse effects are common and frequently cause patients to stop treatment. Following the recent launch of oxybutynin in a transdermal patch formulation in Spain, we undertook a preliminary study to assess treatment response and adverse effects in patients with hyperhidrosis. MATERIAL AND METHODS: This prospective study of 25 patients treated twice weekly with transdermal oxybutynin patches over 10 weeks assessed treatment response on 2 subjective scales: the Hyperhidrosis Disease Severity Scale (HDSS) and a visual analog scale (VAS) for sweating...
December 2016: Actas Dermo-sifiliográficas
keyword
keyword
110797
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"